Extensively drug-resistant tuberculosis in a young child after travel to India

Lancet Infect Dis. 2015 Dec;15(12):1485-91. doi: 10.1016/S1473-3099(15)00356-4. Epub 2015 Nov 16.

Abstract

Extensively drug-resistant (XDR) tuberculosis is becoming increasingly prevalent worldwide, but little is known about XDR tuberculosis in young children. In this Grand Round we describe a 2-year-old child from the USA who developed pneumonia after a 3 month visit to India. Symptoms resolved with empirical first-line tuberculosis treatment; however, a XDR strain of Mycobacterium tuberculosis grew in culture. In the absence of clinical or microbiological markers, low-radiation exposure pulmonary CT imaging was used to monitor treatment response, and guide an individualised drug regimen. Management was complicated by delays in diagnosis, uncertainties about drug selection, and a scarcity of child-friendly formulations. Treatment has been successful so far, and the child is in remission. This report of XDR tuberculosis in a young child in the USA highlights the risks of acquiring drug-resistant tuberculosis overseas, and the unique challenges in management of tuberculosis in this susceptible population.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Child, Preschool
  • Extensively Drug-Resistant Tuberculosis / diagnosis*
  • Extensively Drug-Resistant Tuberculosis / diagnostic imaging
  • Extensively Drug-Resistant Tuberculosis / drug therapy
  • Extensively Drug-Resistant Tuberculosis / microbiology
  • Female
  • Humans
  • India
  • Mycobacterium tuberculosis / pathogenicity
  • Mycobacterium tuberculosis / physiology
  • Pneumonia, Bacterial / diagnosis*
  • Pneumonia, Bacterial / diagnostic imaging
  • Pneumonia, Bacterial / drug therapy
  • Pneumonia, Bacterial / microbiology
  • Radiography
  • Travel
  • Tuberculosis, Pulmonary / diagnosis*
  • Tuberculosis, Pulmonary / diagnostic imaging
  • Tuberculosis, Pulmonary / drug therapy
  • Tuberculosis, Pulmonary / microbiology
  • United States

Substances

  • Antitubercular Agents